Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 45 papers were listed this time. Here's a few in our areas of research interest:
Kondo M, Hoshi SL, Ishiguro H, et al. Economic evaluation of the 70-gene prognosis-signature (MammaPrint(®)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat. 2012 Feb 8. [Epub ahead of print] PubMed PMID: 22315134.
Schwenkglenks M, Toward TJ, Plent S, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012 Feb 7. [Epub ahead of print] PubMed PMID: 22313548.
Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer. Oncologist. 2012 Feb 2. [Epub ahead of print] PubMed PMID: 22302231.
Hedden L, Kennecke H, Villa D, et al. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. Eur J Cancer. 2012 Feb 9. [Epub ahead of print] PubMed PMID: 22325838.
